The vaccine, already approved for adults, was approved for pregnant women to protect infants from birth up to six months from complications caused by respiratory syncytial virus.
Pfizer Inc.’s respiratory syncytial virus (RSV) vaccine Abrysvo was approved by the US Food and Drug Administration to be administered to pregnant women to protect infants at birth, a first for vaccine development.
Abrysvo had already been approved by the FDA for older adults in May and recommended for use by the Centers...
The approval for young children, consistent with the FDA’s new COVID-19 vaccine policy, restricts Spikevax to those with conditions putting them at higher risk.
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
With positive relative efficacy data for its mRNA seasonal flu shot, Moderna hopes to file mRNA-1010 for US approval and refile a COVID-19/flu combo shot that it withdrew in May.
